
Opinion|Videos|September 10, 2024
Case Study: Diagnosing and Managing BPH in a Male Patient With Urinary Symptoms
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Patient Case Example: A man in his late 60s who presents with the following:
- History of straining to initiate and maintain a urinary stream, a weak and intermittent urinary stream, a sensation of incomplete bladder emptying after urination, and nocturia; absence of hematuria or dysuria.
- Past Medical History:
- No history of urinary tract infections or other urological conditions
- Hypertension (well-controlled with medication)
- Hyperlipidemia
- No previous surgical history
- Physical Examination:
- Digital rectal examination reveals an enlarged, nonnodular prostate (approximately 50 g); no other significant findings.
- Laboratory and Diagnostic Tests: Serum prostate-specific antigen level: 2.5 ng/mL; urinalysis: normal; uroflowmetry: peak flow rate of 8 mL/sec (borderline obstructed); post-void residual urine volume: 120 mL; transrectal ultrasound: prostate volume estimated at 55 g.
- Please describe your approach to diagnosing, treating, and managing this patient.
Advertisement
Related to this article

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
4
ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC
5

